PVLA
Palvella Therapeutics, Inc.
PVLA
Palvella Therapeutics, Inc.
Palvella advances QTORIN rapamycin, targeting microcystic lymphatic malformations, with positive Phase 3 SELVA data and a rolling NDA submission underway. PVLA leverages a repeatable regulatory and co
Palvella Therapeutics NASDAQ: PVLA is advancing topical therapies for serious rare skin diseases and vascular malformations that lack FDA-approved treatments, with its lead candidate, QTORIN rapamycin
Palvella Therapeutics, Inc. (PVLA) Q2 2026 Earnings Call Transcript